Don L. Gibbons
Papers
3
Total Citations
141
H-Index
3
About
Don L. Gibbons is a leading thoracic oncologist and translational researcher whose work is reshaping the treatment landscape for non–small cell lung cancer (NSCLC). His primary research focus lies in neoadjuvant immunotherapy—administering immune checkpoint inhibitors before surgery to improve outcomes in resectable disease. Dr. Gibbons is the principal investigator of the landmark NEOSTAR study, which demonstrated that combining nivolumab with ipilimumab prior to surgery yields high pathologic response rates and manageable toxicity in NSCLC patients. His most cited paper (2022, 94 citations) reports surgical outcomes from this trial, showing that neoadjuvant immunotherapy does not compromise the feasibility or safety of subsequent lung resection. Subsequent work (2023, 19 citations) extends these findings by evaluating chemotherapy plus dual checkpoint blockade. Beyond these clinical trials, Dr. Gibbons has contributed to understanding the tumor microenvironment and mechanisms of immune resistance. His work has directly influenced practice guidelines and opened new avenues for personalized, immune-based neoadjuvant strategies. For students and researchers, Gibbons exemplifies how rigorous clinical investigation can translate into tangible improvements in cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3